查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2046138

法布瑞氏症治療市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物、治療方法、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

Fabry Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drugs, By Treatment, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球法布瑞氏症治療市場預計將從 2025 年的 19.4 億美元成長到 2031 年的 28.1 億美元，複合年成長率為 6.37%。

該市場專注於提供酵素替代療法 (ERT) 和Chaperone療法，旨在治療基因突變引起的α-半乳糖苷酶A缺乏症。市場的主要促進因素包括新生兒篩檢計畫的廣泛實施以及有利於孤兒藥研發的監管環境。這些因素有助於早期診斷患者，並鼓勵製藥公司投資於罕見疾病治療。例如，到2025年，法布瑞氏症國際網路將統籌57個國家的61個成員組織，這凸顯了全球診斷和支援活動的強大基礎設施，這將促進市場成長。然而，高昂的終身治療費用構成了報銷的重大障礙，並對市場擴張構成了相當大的阻礙。醫療保健系統和患者個人都承受著沉重的經濟負擔，這限制了已通過核准治療方法的可近性，尤其是在公共醫療預算有限的地區，導致市場滲透率持續面臨挑戰。

市場概覽
預測期 2027-2031
市場規模：2025年 19.4億美元
市場規模：2031年 28.1億美元
複合年成長率：2026-2031年 6.37%
成長最快的細分市場 網路藥房
最大的市場 北美洲

市場促進因素

推動市場發展的關鍵因素之一是新型療法和基因療法的強大臨床研發管線。這些療法正從根本上改變市場方向，從持續的酵素替代療法轉向可能治癒的單次治療。製藥公司正積極開發基因編輯和mRNA技術，以針對α-半乳糖苷酶A缺乏症的根本遺傳病因，旨在使患者終身無需每兩週接受一次靜脈輸液治療。臨床試驗監管方面的重大進展為這一快速的治療進展提供了支持。例如，2025年5月，Sangamo Therapeutics公司確認，其基因治療候選藥物ST-920的I/II期STAAR試驗的所有患者均已完成生技藥品核准申請（BLA）所需的12個月隨訪，從而有望獲得早期核准。這表明根治性治療方法即將商業化，並吸引了大量投資。同時，酵素替代療法（ERT）的持續需求，得益於其已證實的療效和不斷成長的確診患者數量，也繼續支撐著市場的近期財務表現。隨著新生兒篩檢計畫發現的患者數量不斷增加，靜脈輸液療法這項標準治療方法仍然是該行業的主要收入來源。 2025年1月，賽諾菲公司報告稱，其旗艦酶替代療法藥物法布酶（Fabrazyme）在2024年第四季度的銷售額達到2.69億歐元，同比成長12.4%，主要得益於患者治療依從性的提高和新患者入組人數的增加。儘管酵素替代療法佔據主導地位，但其他有價值的替代療法也在推動市場發展。例如，Amicus Therapeutics公司累計，其口服Chaperone藥物Galafold在2024年全年的淨產品銷售額為4.581億美元，年增18%。這顯示全球治療領域呈現出健康且多元化的經濟態勢。

市場挑戰

終身酵素替代療法和Chaperone療法的高昂費用構成了一道巨大的經濟障礙，直接阻礙了全球法布瑞氏症治療市場的成長。儘管診斷技術的進步導致臨床需求不斷成長，但每位患者的高昂費用迫使醫療支付方和保險公司採取嚴格的成本控制措施。這些措施通常包括嚴格的核准前流程、延長保險覆蓋範圍的核准時間，甚至直接拒絕報銷。因此，藥物獲得監管部門核准與其實際上城市之間存在時間差，阻礙了製藥開發商觸及目標患者群體，並限制了收入成長。這項挑戰的影響在藥物核准與患者獲得治療之間的時間差不斷擴大上體現得淋漓盡致。根據歐洲製藥製造商協會聯合會 (EFPIA) 發布的 2025 年報告，歐洲患者獲得創新藥物的平均等待時間將延長至 578 天，而且只有 29% 的經中央核准的治療方法能夠透過公共報銷計畫完全覆蓋。這些數據凸顯了財務和報銷障礙如何有效地限制了市場滲透，即使存在有效的治療方法，也使得只有一部分合格的患者能夠獲得核准的治療方法。

市場趨勢

酵素替代療法 (ERT) 作為第二代長效生技改良藥，其引入從根本上改變了標準治療模式，減輕了傳統雙週輸注帶來的沉重治療負擔。與第一代 ERT 相比，這些先進的聚乙二醇化製劑透過化學修飾延長了血漿半衰期並降低了免疫抗原性，從而有望減少給藥頻率並提高患者的長期依從性。隨著醫療專業人員越來越傾向於選擇兼具療效和便利性的治療方法，這種向最佳化生物製藥的轉變正迅速取代傳統治療方法。例如，凱西製藥 (Chiesi Pharmaceutici) 於 2025 年 4 月報告稱，其全球罕見疾病業務部門 2024 年全年銷售額達 7.63 億歐元，同比成長 41%，主要得益於其長效療法 Elfabrio 的成功商業性擴張。同時，新型基材減少療法的開發也為不適合接受Chaperone療法的患者提供了口服治療選擇，從而豐富了治療方案。這些小分子化合物透過抑制葡糖基神經醯胺合成酶發揮作用，在酵素缺乏之前阻止Globotriaosylceramide的積累，從而提供了一種獨特的作用機制，與外用酵素相比，可能具有更好的組織滲透性。製藥公司正致力於收集可靠的長期數據，以證實該方法在穩定心臟和腎臟功能方面的有效性。 2025年4月，賽諾菲推進了口服抑制劑benklustat的第三期CARAT試驗。該試驗計劃持續長達5.3年，以評估其在降低左心室品質方面的持續療效。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：法布瑞氏症治療的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依藥物分類（阿加糖酶BETA、米加司他、其他）
    • 治療方法（酵素替代療法（ERT）、Chaperone療法、基材減少療法（SRT）等）
    • 給藥途徑（口服、腸外、其他）
    • 分銷通路（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美法布瑞氏症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲法布瑞氏症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區法布瑞氏症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲法布瑞氏症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲法布瑞氏症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球法布瑞氏症治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Genzyme Corporation
  • Takeda Pharmaceutical Company Limited
  • Amicus Therapeutics, Inc
  • ISU ABXIS Co Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • Protalix BioTherapeutics Inc.
  • Chiesi Farmaceutici SpA
  • Freeline Therapeutics Holdings PLC
  • Yuhan Corporation
  • M6P Therapeutics Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18737

The Global Fabry Disease Treatment Market is projected to expand from USD 1.94 Billion in 2025 to USD 2.81 Billion by 2031, demonstrating a compound annual growth rate (CAGR) of 6.37%. This market focuses on delivering enzyme replacement therapies (ERT) and chaperone treatments, which are designed to counteract the alpha-galactosidase A deficiency stemming from genetic mutations. Key drivers include the broader adoption of newborn screening initiatives and supportive regulatory landscapes that promote the development of orphan drugs. These factors contribute to earlier patient diagnosis and encourage pharmaceutical companies to invest in treatments for rare diseases; for instance, the Fabry International Network coordinated 61 member associations across 57 countries in 2025, highlighting a robust global infrastructure for diagnosis and advocacy that fuels market growth.Nevertheless, market expansion faces considerable obstacles due to the prohibitive cost of lifelong treatment, which establishes significant hurdles for reimbursement. The substantial financial strain on both healthcare systems and individual patients limits access to approved therapies, especially in areas with constrained public health budgets, thereby posing an ongoing challenge to achieving wider market penetration.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.94 Billion
Market Size 2031USD 2.81 Billion
CAGR 2026-20316.37%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Market Driver

A significant market driver is the robust clinical pipeline of novel therapeutics and gene therapies, which is fundamentally altering the market's direction from ongoing enzyme management towards potentially curative, one-time interventions. Pharmaceutical companies are actively developing gene editing and mRNA technologies to target the underlying genetic cause of alpha-galactosidase A deficiency, aiming to eliminate the need for lifelong, bi-weekly infusions. This swift therapeutic progress is demonstrated by key regulatory advancements in clinical trials; for example, Sangamo Therapeutics confirmed in May 2025 that all patients in the Phase 1/2 STAAR study of their gene therapy candidate ST-920 had completed the 12-month follow-up necessary for an accelerated approval Biologics License Application, indicating that curative options are nearing commercial availability and drawing considerable investment.Concurrently, the sustained demand for Enzyme Replacement Therapies (ERT) continues to underpin the market's immediate financial performance, driven by proven efficacy and an expanding number of diagnosed patients. As newborn screening programs enlarge the identified patient population, standard-of-care infusion therapies remain the primary source of revenue for the industry. Sanofi reported in January 2025 that sales for its core ERT, Fabrazyme, reached €269 million in Q4 2024, a 12.4% increase mainly due to better treatment adherence and new patient enrollments. While ERT holds a dominant position, the market is also strengthened by valuable alternative treatments; Amicus Therapeutics, for instance, generated $458.1 million in net product sales for its oral chaperone Galafold in full-year 2024, marking an 18% year-over-year growth that highlights the healthy and diverse economic state of the global treatment sector.

Market Challenge

The exorbitant cost associated with lifelong enzyme replacement and chaperone therapies presents a significant economic barrier, directly impeding the growth of the Global Fabry Disease Treatment Market. Despite increasing clinical demand spurred by improved diagnostics, the high per-patient expense compels healthcare payers and insurance providers to enforce stringent cost-containment strategies. These often include strict prior authorization processes, protracted coverage decisions, or outright denials of reimbursement. Consequently, a gap emerges between a drug's regulatory approval and its actual commercial adoption, hindering pharmaceutical developers from reaching the entire eligible patient demographic and stifling revenue expansion.The consequences of this challenge are evident in the growing delays between drug approval and patient access. As reported by the European Federation of Pharmaceutical Industries and Associations in 2025, the average waiting period for patients to receive innovative medicines across Europe rose to 578 days, with only 29% of centrally approved treatments being fully accessible via public reimbursement systems. These figures underscore how financial and reimbursement obstacles effectively cap market penetration, limiting the availability of approved therapies to only a segment of eligible patients, even when effective treatments exist.

Market Trends

The introduction of second-generation, long-acting biobetter Enzyme Replacement Therapies (ERTs) is fundamentally transforming the standard of care, mitigating the substantial treatment burden linked with conventional bi-weekly infusions. In contrast to first-generation ERTs, these advanced PEGylated formulations employ chemical modifications to prolong plasma half-life and decrease immunogenicity, potentially enabling less frequent dosing and enhancing long-term patient adherence. This transition towards optimized biologics is quickly gaining market share from older treatments, as healthcare providers increasingly favor therapies that combine efficacy with greater convenience for patients. Chiesi Farmaceutici, for example, reported in April 2025 that its Global Rare Diseases unit generated €763 million in full-year 2024 revenues, a 41% surge largely attributable to the successful commercial expansion of its long-acting therapy, Elfabrio.Concurrently, the development of novel substrate reduction therapies is diversifying the treatment landscape by introducing an oral treatment option for patients who are not suitable candidates for chaperone therapies. These small molecules function by inhibiting glucosylceramide synthase, thereby preventing the buildup of globotriaosylceramide prior to the enzymatic defect, offering a distinct mechanism of action that could provide improved tissue penetration compared to externally administered enzymes. Pharmaceutical companies are focusing on generating robust long-term data to confirm the efficacy of this approach in stabilizing cardiac and renal function. Sanofi, in April 2025, progressed its pivotal Phase 3 CARAT study for the oral inhibitor venglustat, which is designed to run for up to 5.3 years to evaluate its sustained effectiveness in reducing left ventricular mass.

Key Market Players

  • Genzyme Corporation
  • Takeda Pharmaceutical Company Limited
  • Amicus Therapeutics, Inc
  • ISU ABXIS Co Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • Protalix BioTherapeutics Inc.
  • Chiesi Farmaceutici S.p.A.
  • Freeline Therapeutics Holdings PLC
  • Yuhan Corporation
  • M6P Therapeutics Inc.

Report Scope

In this report, the Global Fabry Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Fabry Disease Treatment Market, By Drugs

  • Agalsidase Beta
  • Migalastat
  • Others

Fabry Disease Treatment Market, By Treatment

  • Enzyme Replacement Therapy (ERT)
  • Chaperone Treatment
  • Substrate Reduction Therapy (SRT)
  • others

Fabry Disease Treatment Market, By Route of Administration

  • Oral
  • Parenteral
  • others

Fabry Disease Treatment Market, By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online Pharmacies

Fabry Disease Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Fabry Disease Treatment Market.

Available Customizations:

Global Fabry Disease Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Fabry Disease Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drugs (Agalsidase Beta, Migalastat, Others)
    • 5.2.2. By Treatment (Enzyme Replacement Therapy (ERT), Chaperone Treatment, Substrate Reduction Therapy (SRT), others)
    • 5.2.3. By Route of Administration (Oral, Parenteral, others)
    • 5.2.4. By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online Pharmacies)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Fabry Disease Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drugs
    • 6.2.2. By Treatment
    • 6.2.3. By Route of Administration
    • 6.2.4. By Distribution Channel
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Fabry Disease Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drugs
        • 6.3.1.2.2. By Treatment
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Distribution Channel
    • 6.3.2. Canada Fabry Disease Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drugs
        • 6.3.2.2.2. By Treatment
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Distribution Channel
    • 6.3.3. Mexico Fabry Disease Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drugs
        • 6.3.3.2.2. By Treatment
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Distribution Channel

7. Europe Fabry Disease Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drugs
    • 7.2.2. By Treatment
    • 7.2.3. By Route of Administration
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Fabry Disease Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drugs
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. France Fabry Disease Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drugs
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. United Kingdom Fabry Disease Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drugs
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Distribution Channel
    • 7.3.4. Italy Fabry Disease Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drugs
        • 7.3.4.2.2. By Treatment
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Distribution Channel
    • 7.3.5. Spain Fabry Disease Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drugs
        • 7.3.5.2.2. By Treatment
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Fabry Disease Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drugs
    • 8.2.2. By Treatment
    • 8.2.3. By Route of Administration
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Fabry Disease Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drugs
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. India Fabry Disease Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drugs
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. Japan Fabry Disease Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drugs
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. South Korea Fabry Disease Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drugs
        • 8.3.4.2.2. By Treatment
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Australia Fabry Disease Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drugs
        • 8.3.5.2.2. By Treatment
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Fabry Disease Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drugs
    • 9.2.2. By Treatment
    • 9.2.3. By Route of Administration
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Fabry Disease Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drugs
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. UAE Fabry Disease Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drugs
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. South Africa Fabry Disease Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drugs
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Distribution Channel

10. South America Fabry Disease Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drugs
    • 10.2.2. By Treatment
    • 10.2.3. By Route of Administration
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Fabry Disease Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drugs
        • 10.3.1.2.2. By Treatment
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Colombia Fabry Disease Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drugs
        • 10.3.2.2.2. By Treatment
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. Argentina Fabry Disease Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drugs
        • 10.3.3.2.2. By Treatment
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Fabry Disease Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Genzyme Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Takeda Pharmaceutical Company Limited
  • 15.3. Amicus Therapeutics, Inc
  • 15.4. ISU ABXIS Co Ltd.
  • 15.5. JCR Pharmaceuticals Co., Ltd.
  • 15.6. Protalix BioTherapeutics Inc.
  • 15.7. Chiesi Farmaceutici S.p.A.
  • 15.8. Freeline Therapeutics Holdings PLC
  • 15.9. Yuhan Corporation
  • 15.10. M6P Therapeutics Inc.

16. Strategic Recommendations

17. About Us & Disclaimer